High mobility group nucleosomal binding domain 2 pseudogene 39 (HMGN2P39)

High mobility group nucleosomal binding domain 2 pseudogene 39 (HMGN2P39) is a human **pseudogene**, meaning it is a genomic segment similar to a functional gene but generally considered nonfunctional due to acquired mutations or loss of regulatory elements[6][9]. It is located on chromosome 13 (13:59010332-59010604)[5], and annotated in gene databases as a noncoding genetic element with high sequence similarity to the parent gene, high mobility group nucleosomal binding domain 2 (HMGN2)[5][9]. No protein product or enzymatic activity has been attributed to HMGN2P39[9]. Like other pseudogenes, HMGN2P39 could potentially exert regulatory effects at the RNA level, such as through **competing endogenous RNA** (ceRNA) mechanisms, acting as miRNA decoys, producing noncoding RNAs, or affecting parental gene expression, although there is no direct evidence or literature specifically supporting such a function for HMGN2P39[2][10]. In general, pseudogenes as a family have been described to occasionally impact gene regulation, participate in disease processes through RNA-level regulation, or serve as sources of noncoding RNAs, but the majority—including HMGN2P39—have no well-defined individual function or therapeutic relevance[2][6][9]. There is no evidence that HMGN2P39 is targeted by any drugs, serves as a biomarker, or has safety concerns associated with its manipulation. It is *not* considered a therapeutic target[9].

Other names

HMGN2P39